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doi:10.1016/j.jfma.2012.01.007Glycated hemoglobin A1c (HbA1c) is an important indicator of glycemic control. The current
recommendation for glycemic control based on HbA1c values has been widely accepted.
However, HbA1c values depend on the lifespan of erythrocytes and the assay methods used.
Here, we report the case of a patient with type 2 diabetes with unusual falling of HbA1c
due to interference from dapsone treatment for leukocytoclastic vasculitis. He was
a 52-year-old man, who was diagnosed with type 2 diabetes mellitus 5 years previously and
who had been treated in our hospital in the past 3 years. Glycemia was controlled by sulfonyl-
urea and metformin. During the 3-years follow-up period, HbA1c dropped significantly during
the addition of dapsone treatment, although plasma glucose levels remained stable. HbA1c
levels were raised after discontinuation of dapsone. With rechallenge of dapsone usage, HbA1c
decreased again. We conclude that dapsone may be the cause of artificially low HbA1c. Other
measurements to monitor glycemic control should be considered when dapsone is used for the
treatment of concurrent disorders, such as autoimmune disease and pneumocystis jiroveci
pneumonia.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Dapsone (4,4’-diaminodiphenylsulfone, a synthetic sulfone)




ight ª 2012, Elsevier Taiwan LLCinflammatory action, dapsone has become one of the major
treatments for autoimmuneand allergicdisorders.1e3 In post-
transplanted or human immunodeficiency virus-infected
patients, dapsone is an alternative drug for prophylaxis of
pneumocystis jiroveci pneumonia. In this report, we describe
a fall in glycated hemoglobin A1c (HbA1c) readings when
a diabetic patient received dapsone treatment. We also
discuss the possible mechanisms of artificially low HbA1c
when a diabetic patient is co-treated with dapsone.& Formosan Medical Association. All rights reserved.
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This male patient, born in 1956, was diagnosed with type 2
diabetes mellitus in 2003 and treated with sulfonylurea and
metformin from then onwards. He visited our hospital in
July 2005 for examination of purpura over the lower limbs.
Skin biopsy showed leukocytoclastic vasculitis, for which
dapsone 100 mg per day was prescribed from December
2005. He tolerated dapsone well except his hemoglobin
levels decreased from 14.3 g/dL to 12.3 g/dL in half a year.
Hematologic assessment showed a mean corpuscular
volume (MCV) of 106.5 fL; reticulocytes 2.92%; and reticu-
locyte production index 1.62 in June 2006. For macrocytic
anemia and reticulocytosis, the patient received dapsone-
induced hemolysis. He was transferred to our diabetic
clinic for further diabetic care in June 2006. Examination
showed no nephropathy, retinopathy, neuropathy, or
abnormal ankle brachial index. The initial fasting plasma
glucose was 144 mg/dL, postprandial plasma glucose
141 mg/dL, and HbA1c 4.4% (collected in a fluoride-EDTA-
containing tube; assay method used: high-performance
liquid chromatography, Primus CLC385, Kansas city, USA,
reference range: 3.8e6.0%). The estimated average
glucose4 derived from HbA1c was 79.58 mg/dL (Fig. 1). The
patient did not report any hypoglycemic symptoms. He was
treated with oral metformin 850 mg and modified-release
gliclazide 30 mg per day from July 2006.
In September 2006, cutaneous vasculitis improved and
dapsone was discontinued. The HbA1c increased to 6.2%
3-months later without any change of oral antidiabetic
agents or lifestyle. He did not complain of any hypergly-
cemic symptoms, such as polyuria, polydipsia or weight
loss. The oral antidiabetic agents were changed to glime-
piride 2 mg and metformin 850 mg per day in December
2006. The HbA1c ranged from 5.7 to 7.6%, fasting plasmaFigure 1 Interference of HbA1c readings in a patient receiving da
plasma glucose; eAG: estimated average glucose valueZ (HbA1c*2glucose 112 to 103 mg/dL, and postprandial plasma glucose
109 to 117 mg/dL in the following 6 months.
New purpura lesions recurred and dapsone was then
restarted in August 2007. Three months later, the patient’s
HbA1c level was reported to as low as 4.1% when the fasting
plasma glucose was 123 mg/dL and 2-hr postprandial
plasma glucose 110 mg/dL. The estimated average glucose
derived from HbA1c was 70.97 mg/dL. Antidiabetic treat-
ment was adjusted to only metformin 850 mg per day from
then on. Fasting glycemia was elevated to 158 mg/dL and
postprandial glycemia to 154 mg/dL; however, we observed
that HbA1c remained low at around 4.2% to 5.5%. Hemo-
globin electrophoresis was checked and results showed
no elevated hemoglobin H, hemoglobin A2 or hemoglobin
F. From February 2009, dapsone was discontinued again
because of short supply. We found that HbA1c increased to
6.2% 2-months later when fasting glycemia was 132 mg/dL
and postprandial glycemia 137 mg/dL. The patient’s
hemogram results also recovered: hemoglobin increased
from 10.3 to 13.3 g/dL, MCV from 105.4 to 96.9 fL, and
reticulocyte percentage from 2.55 to 0.74% in 3 months.Discussion
This patient received dapsone to treat cutaneous condition
of leukoclastic vasculitis with a good response but did not
achieve complete remission. During a period of over 3
years, we observed an abrupt reduction of HbA1c during
two courses of dapsone treatment for recurrent cutaneous
lesions. His HbA1c increased to 7.6% after the first course of
dapsone treatment. Similar changes in the HbA1c were also
observed during the second course of dapsone treatment
(Fig. 1). In the literature, low HbA1c induced by dapsone
has been reported in one study of NOD mice5 and six casepsone treatment. AC: fasting plasma glucose; PC: postprandial
8.7)-46.7 mg/dL4.
Dapsone with false HbA1c readings 111reports in humans.6e11 To our knowledge, this is the first
case showing recurrent low HbA1c after repeated admin-
istration of dapsone.
HbA1 is a negative hemoglobin and can be detected by
caution-exchange chromatography, which was first re-
ported by Allen in 1958.12 HbA1 can be further divided into
different components, including HbA1a, HbA1b and HbA1c.
HbA1c was formed by non-enzymatic condensation of
glucose with the N-terminal valine residues of the b-chains
of hemoglobin. Initially, glucose condensates bind hemo-
globin to form an unstable Schiff base. After Amadori
rearrangement, the labile Schiff base switches into a stable
ketoamine (1-deoxy, 1-aminofructose). Glucose conden-
sates also bind to the NH2-terminal valine of the a-chain
and certain epsilon amino groups of the lysine residues on
the a- and b-chains.13 HbA1c values depend on erythrocyte
lifespan and the assay methods used. Some conditions,
such as kidney disease, erythropoietin injection,14 hemo-
lytic anemia,15 hemoglobinopathy,16 or chronic lymphocytic
leukemia17 can affect HbA1c measurements. This patient
had macrocytic anemia. Although metformin may decrease
intestinal absorption of vitamin B12 and folic acid, it
rarely causes anemia. Besides, the MCV was around
102.1-109.8 fL, which was not large enough to reach the
criteria of megaloblastic anemia. Non-megaloblastic causes
were considered, including hemolytic anemia, hemorrhage,
alcohol, hypothyroidism, and bone marrow disorders.18 This
patient didn’t have any symptom of bleeding or hypothy-
roidism. Also, his reticulocyte percentage increased during
administration of dapsone and decreased after discontinu-
ation of dapsone. Dapsone may reduce the survival life of
erythrocytes and aged erythrocytes are susceptible to
hemolysis.19 Metformin-induced hemolysis has also been
reported,20 but this case received metformin continuously
and the dosage did not change. After discontinuation of
dapsone, hemoglobin increased and reticulocyte decreased
remarkably. Therefore, dapsone-induced hemolysis was the
most likely cause of his anemia and low HbA1c.
There are many methods for measurement of HbA1c.
These methods are mostly based on either cation
differences (such as in cation-exchange chromatography,
electrophoresis, and isoelectric focusing) or structural
differences (such as in affinity chromatography and immu-
noassay).21 Our hospital uses Primus CLC 385 to quantify
HbA1c. The HbA1c results indirectly come from the
measurement of total glycated hemoglobin by the boronate
affinity method. Elevated fetal hemoglobin would artifi-
cially lower HbA1c on Primus CLC 385.22 However, a hemo-
globin variant is probably not the cause of low HbA1c in this
patient because HbA1c raised and fell several times. The
hemoglobin electrophoresis also revealed no elevated
hemoglobin H, hemoglobin A2 or hemoglobin F.
Since the lifespan of erythrocyte is 120 days, we can
use HbA1c to predict the average plasma glucose in the
previous 3 months.13 In this case, we saw the patient’s
estimated average glucose calculated by HbA1c was
much lower than fasting plasma glucose and 2-hour post-
prandial glucose during dapsone therapy (Fig. 1). In addi-
tion to dapsone-induced hemolysis, another explanation is
dapsone-induced oxygen stress. Hydroxylamine, a dapsone
metabolite, reacts with oxyhemoglobin (Fe2þ) to form
methemoglobin (Fe3þ). The process of methemoglobinformation depletes reduced glutathione, then generates
reactive oxygen species and impairs antioxidant defenses.23
In one study in non-insulin-dependent diabetic patients,
HbA1c levels were significantly negatively correlated with
scavenging capacity of oxygen radicals.24 HbA1c production
is also decreased under oxygen tension.25
This case report has some limitations. First, fructos-
amine was unavailable and so was not used for appropriate
monitoring of glycemic control. Previous reports have
shown that fructosamine is not changed under conditions
of hemolysis and dapsone treatment.7,11 Second, we did
not check haptoglobin, lactate dehydrogenase, or serum
unconjugated bilirubin to make the definite diagnosis of
hemolytic anemia. However, dapsone-induced hemolysis
should be suspected by macrocytic anemia and retic-
ulocytosis during dapsone treatment.
In conclusion, dapsone is commonly used in diabetic
patients who have autoimmune disease or who are immu-
nocompromised. Doctors should be aware that HbA1c levels
can be misread as indicating good glycemic control when in
fact they are due to dapsone interference. Other tests,
such as blood glucose, urine glucose, glycated serum
protein, and fructosamine are alternatives to monitor gly-
cemic control in patients treated with dapsone.References
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